Limits...
An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts.

Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, Verschuuren JJ, Tallaksen CM - Health Qual Life Outcomes (2015)

Bottom Line: The mean HRQOL score was lower in patients with bulbar and generalized symptoms (p < 0.001) compared to sex and age adjusted healthy controls, but not in patients with ocular symptoms or patients in remission.Multivariate analysis revealed that female gender, generalized symptoms and use of secondary immunosuppressive drugs at the time of testing were risk factors for reduced HRQOL.Historically, the HRQOL levels have not changed since 2001 and no new clinical predictors could be detected in this exhaustive population-based study.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Oslo University Hospital, Ullevål and Rikshospitalet, Ullevål, Pb. 4950 Nydalen, 0424, Oslo, Norway. marbol@ous-hf.no.

ABSTRACT

Unlabelled: Current available therapies control Myasthenia gravis (MG) reasonably well, but Health Related Quality of life (HRQOL) remains lower than expected. The aim was provide insights in how HRQOL in MG stands across borders and time, compare the scores to general population controls and other chronic disorders and assess the impact of potential predictors for quality of life such as a) clinical characteristics b) antibodies c) thymoma and d) treatment in a population-based cohort.

Methods: We designed a population-based cross-sectional study including 858 patients, 373 from Norway and 485 from the Netherlands. The Short Form Health Survey 36 (SF-36) and a cross-cultural validated questionnaire were used. Data were in addition compared to the general population, other chronic diseases and previous studies.

Results: Mean physical composite score was 59.4 and mental composite score 69.0 with no differences between the countries. The mean HRQOL score was lower in patients with bulbar and generalized symptoms (p < 0.001) compared to sex and age adjusted healthy controls, but not in patients with ocular symptoms or patients in remission. Multivariate analysis revealed that female gender, generalized symptoms and use of secondary immunosuppressive drugs at the time of testing were risk factors for reduced HRQOL.

Conclusions: Remission and absence of generalized symptoms were favorable factors for HRQOL in MG patients. Historically, the HRQOL levels have not changed since 2001 and no new clinical predictors could be detected in this exhaustive population-based study. Further studies should explore the impact of non clinical factors like ethnic variations, socio-economic and hormonal factors on HRQOL.

No MeSH data available.


Related in: MedlinePlus

HRQOL in Myasthenia Gravis compared with healthy controls. The figure illustrates the population based MG cohorts in Netherlands (a) and the Norway (b) compared with healthy controls from their own countries. Healthy control data is provided by Loge et al.; Norway [24] and Aaronesen et al. [22]. In summary, MG patients scored lower than healthy controls and females scored lower than males and those in remission similar to healthy controls. The Score range from 0-100. Higher score indicate better Health related quality of life (HRQOL). Solid line is score of reference population for men, and dotted line is score of reference population for women in their respective countries. Horizontal axes show the 8 domains of SF-36 and composite scores
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4522107&req=5

Fig2: HRQOL in Myasthenia Gravis compared with healthy controls. The figure illustrates the population based MG cohorts in Netherlands (a) and the Norway (b) compared with healthy controls from their own countries. Healthy control data is provided by Loge et al.; Norway [24] and Aaronesen et al. [22]. In summary, MG patients scored lower than healthy controls and females scored lower than males and those in remission similar to healthy controls. The Score range from 0-100. Higher score indicate better Health related quality of life (HRQOL). Solid line is score of reference population for men, and dotted line is score of reference population for women in their respective countries. Horizontal axes show the 8 domains of SF-36 and composite scores

Mentions: binformation derived from medical charts


An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts.

Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, Verschuuren JJ, Tallaksen CM - Health Qual Life Outcomes (2015)

HRQOL in Myasthenia Gravis compared with healthy controls. The figure illustrates the population based MG cohorts in Netherlands (a) and the Norway (b) compared with healthy controls from their own countries. Healthy control data is provided by Loge et al.; Norway [24] and Aaronesen et al. [22]. In summary, MG patients scored lower than healthy controls and females scored lower than males and those in remission similar to healthy controls. The Score range from 0-100. Higher score indicate better Health related quality of life (HRQOL). Solid line is score of reference population for men, and dotted line is score of reference population for women in their respective countries. Horizontal axes show the 8 domains of SF-36 and composite scores
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4522107&req=5

Fig2: HRQOL in Myasthenia Gravis compared with healthy controls. The figure illustrates the population based MG cohorts in Netherlands (a) and the Norway (b) compared with healthy controls from their own countries. Healthy control data is provided by Loge et al.; Norway [24] and Aaronesen et al. [22]. In summary, MG patients scored lower than healthy controls and females scored lower than males and those in remission similar to healthy controls. The Score range from 0-100. Higher score indicate better Health related quality of life (HRQOL). Solid line is score of reference population for men, and dotted line is score of reference population for women in their respective countries. Horizontal axes show the 8 domains of SF-36 and composite scores
Mentions: binformation derived from medical charts

Bottom Line: The mean HRQOL score was lower in patients with bulbar and generalized symptoms (p < 0.001) compared to sex and age adjusted healthy controls, but not in patients with ocular symptoms or patients in remission.Multivariate analysis revealed that female gender, generalized symptoms and use of secondary immunosuppressive drugs at the time of testing were risk factors for reduced HRQOL.Historically, the HRQOL levels have not changed since 2001 and no new clinical predictors could be detected in this exhaustive population-based study.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, Oslo University Hospital, Ullevål and Rikshospitalet, Ullevål, Pb. 4950 Nydalen, 0424, Oslo, Norway. marbol@ous-hf.no.

ABSTRACT

Unlabelled: Current available therapies control Myasthenia gravis (MG) reasonably well, but Health Related Quality of life (HRQOL) remains lower than expected. The aim was provide insights in how HRQOL in MG stands across borders and time, compare the scores to general population controls and other chronic disorders and assess the impact of potential predictors for quality of life such as a) clinical characteristics b) antibodies c) thymoma and d) treatment in a population-based cohort.

Methods: We designed a population-based cross-sectional study including 858 patients, 373 from Norway and 485 from the Netherlands. The Short Form Health Survey 36 (SF-36) and a cross-cultural validated questionnaire were used. Data were in addition compared to the general population, other chronic diseases and previous studies.

Results: Mean physical composite score was 59.4 and mental composite score 69.0 with no differences between the countries. The mean HRQOL score was lower in patients with bulbar and generalized symptoms (p < 0.001) compared to sex and age adjusted healthy controls, but not in patients with ocular symptoms or patients in remission. Multivariate analysis revealed that female gender, generalized symptoms and use of secondary immunosuppressive drugs at the time of testing were risk factors for reduced HRQOL.

Conclusions: Remission and absence of generalized symptoms were favorable factors for HRQOL in MG patients. Historically, the HRQOL levels have not changed since 2001 and no new clinical predictors could be detected in this exhaustive population-based study. Further studies should explore the impact of non clinical factors like ethnic variations, socio-economic and hormonal factors on HRQOL.

No MeSH data available.


Related in: MedlinePlus